Share

A New Chapter of the Biotech Social Pact is Launched in Portugal

On 19th September at the BioMeet 2022 Congress in in Oeiras, Portugal, the Portuguese Chapter of the BSP was officially launched. We are overjoyed that the BSP and its mission continues to grow across Europe!

The Pact was signed by no less than 14 Portuguese biotech leaders in the company of an esteemed audience, which included Portuguese Minister for Economy and Maritime Industry António Costa Silva, who congratulated and welcomed the signature of the new BSP chapter in Portugal in his closing remarks.

Not only does this represent exciting growth of the BSP into the Portuguese space, but has brought with it several new members of the project. We would like to extend a warm welcome to our new signatories:

  • António Portela, CEO, BIAL
  • Bruno Santos, CEO, Immunethep
  • Pedro Castanheira, Head of Protein Sciences, Immunethep
  • Daniela Couto, Partner, BioGeneration Ventures
  • David Braga Malta, Venture Partner, Pictet Private Equity
  • David Cristina, Executive Director, Fosun
  • Filipe Assoreira, ex-CEO, Nano4 Global
  • Henrique Veiga Fernandes, CSO, LiMM Therapeutics
  • José Pereira-Leal, CEO, Ophiomics
  • Paulo Barradas, CEO, Bluepharma
  • Raquel Fortunato, CEO, GenIbet
  • Rui Amandi de Sousa, CEO, Stemmatters
  • Sérgio Simões, CEO, Luzitin
  • Simão Soares, CEO, SilicoLife

We’re particularly thrilled that, with this new influx of signatories, the BSP family has officially grown to over 100!

The BSP received high visibility at the event in the form of posters, banners and leave-behinds. The event was attended by journalists with already two media publications in SAPO and Expresso, as well as an OpEd from Steering Committee members Julien Patris (Alnylam) and Anant Murthy (argenx) published in Observador.

The event was live streamed and a recording is available here.

We are immensely grateful to P-BIO and Expresso for their support and collaboration in preparation for this milestone event.

The Biotech Social Pact gathers CEOs and leaders of biotech and life sciences who are committed to working alongside high-level policymakers and health authorities to sustainably grow the biotech ecosystem whilst ensuring timely and widespread access to innovative treatments for patients and health systems across Europe. The Biotech Social Pact does not necessarily reflect the policies or positions of the agencies, organizations, employers, or companies with which the signatories are affiliated. United in upholding common principles and beliefs, our members are diverse assembly of leading organisations that are often not represented in trade associations, including pre- and early commercial companies, venture capital firms and individual industry leaders. The BSP is not a trade association and coexists alongside existing biopharma trade associations. It aims at offering a supporting voice to emerging and rapidly growing global biotech companies and to contribute to awareness of biotech and support the biotech ecosystem at large. Up until 2023, the Biotech Social Pact was managed by Portland, a global Public Affairs company, with the financial support of Alnylam Pharmaceuticals, Amicus and argenx.